Generation Bio, Vir partner for mAbs against COVID-9

By The Science Advisory Board staff writers

March 30, 2020 -- Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes COVID-19.

The collaboration will allow Generation Bio's gene therapy platform, which delivers genetic information to cells without the use of adeno-associated viruses, to be combined with Vir's neutralizing antibodies, the two firms said.

Vir's leading antibody was developed from a patient who recovered from SARS-CoV-1 and could neutralize SARS-CoV-2, according to Generation Bio and Vir.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.